CAR T-Cell Therapy Remains Underutilized, Despite Improvements in Access
Advances in CAR T-cell therapy, FDA approvals, and expert insights help improve cancer patient outcomes and address treatment barriers.
Significant advancements in chimeric antigen receptor (CAR) T-cell therapy have occurred over the past several years as successful clinical trials and FDA approvals have positively impacted patient outcomes. Houston Holmes, MD, MBA, hematologist and medical oncologist at Texas Oncology–Baylor Charles A. Sammons Cancer Center shares the barriers and solutions to CAR-T therapy and what community oncologists do to optimize CAR T-cell therapy for their patients with cancer.
Read the full article at Targeted Oncology.